Showing results (1-10 of 10) with videos related to
Sort By:
Pageof 1
BMC Clinical Pathology|September 29, 2015
Enrichment of the embryonic stem cell reprogramming factors Oct4, Nanog, Myc, and Sox2 in benign and malignant vascular tumorsClarissa N Amaya, Brad A BryanOncoscience|October 3, 2017
Beta-adrenergic receptors are expressed across diverse cancersSteven L Rains, Clarissa N Amaya, Brad A BryanBMC Cancer|July 16, 2017
Rho kinase proteins display aberrant upregulation in vascular tumors and contribute to vascular tumor growthClarissa N Amaya, Dianne C Mitchell, Brad A BryanPathology|July 10, 2017
PD-1 and PD-L1 expression in bone and soft tissue sarcomasAlireza Torabi, Clarissa N Amaya, Frank H Wians, et al.Pathology|February 28, 2017
Enhanced expression of Programmed cell death 1 (PD-1) protein in benign vascular anomaliesClarissa N Amaya, Frank H Wians, Brad A Bryan, et al.JAMA Dermatology|September 17, 2015
Growth Attenuation of Cutaneous Angiosarcoma With Propranolol-Mediated β-BlockadeWilliam Chow, Clarissa N Amaya, Steven Rains, et al.Molecular and Clinical Oncology|August 30, 2018
5-HT serotonin receptors modulate mitogenic signaling and impact tumor cell viabilityYessenia Ballou, Alexandria Rivas, Andres Belmont, et al.Frontiers in Oncology|February 18, 2021
Propranolol Sensitizes Vascular Sarcoma Cells to Doxorubicin by Altering Lysosomal Drug Sequestration and Drug EffluxJhuma Saha, Jong Hyuk Kim, Clarissa N Amaya, et al.Oncoscience|June 2, 2018
Non-selective beta blockers inhibit angiosarcoma cell viability and increase progression free- and overall-survival in patients diagnosed with metastatic angiosarcomaClarissa N Amaya, Mariah Perkins, Andres Belmont, et al.Oncotarget|December 30, 2016
Use of non-selective β-blockers is associated with decreased tumor proliferative indices in early stage breast cancerAlexa Montoya, Clarissa N Amaya, Andres Belmont, et al.Pageof 1